Literature DB >> 19821796

Bone-marrow-derived mesenchymal stem cell therapy for neurodegenerative diseases.

Ofer Sadan1, Eldad Melamed, Daniel Offen.   

Abstract

BACKGROUND: Stem-cell-based therapy is a promising new approach to handling neurodegenerative diseases. One of the most promising cellular sources is bone-marrow-derived mesenchymal stem cells (MSCs) also termed multipotent stromal cells. MSCs represent an autologous source and are abundant and non-tumorigenic. Additionally, MSCs possess the useful characteristics of homing and chemokine secretion. OBJECTIVE/
METHODS: Since neurodegenerative diseases have many pathological processes in common, a specific therapeutic agent could potentially ameliorate the symptoms of several distinct neurodegenerative diseases. In this review we demonstrate the wide variety of mechanisms by which MSCs can influence neurodegenerative processes. RESULTS/
CONCLUSIONS: The mechanisms by which transplanted MSCs influence neurodegenerative diseases can be broadly classified as cellular replacement or paracrine secretion, with the latter subdivided into trophic factor secretion or immunomodulation by cytokines. Emerging research suggests that genetic manipulations before transplantation could enhance the therapeutic potential of MSCs. Such manipulation could turn the cells into a 'Trojan horse', to deliver specific proteins, or promote reprogramming of the MSCs into the neural lineage. Clinical trials testing MSC-based therapies for familial amyotrophic lateral sclerosis and multiple sclerosis are in progress.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19821796     DOI: 10.1517/14712590903321439

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  38 in total

Review 1.  The stem cell niche should be a key issue for cell therapy in regenerative medicine.

Authors:  José Becerra; Leonor Santos-Ruiz; José A Andrades; Manuel Marí-Beffa
Journal:  Stem Cell Rev Rep       Date:  2011-06       Impact factor: 5.739

2.  Mesenchymal stem cells express serine protease inhibitor to evade the host immune response.

Authors:  Najib El Haddad; Dean Heathcote; Robert Moore; Sunmi Yang; Jamil Azzi; Bechara Mfarrej; Mark Atkinson; Mohamed H Sayegh; Jeng-Shin Lee; Philip G Ashton-Rickardt; Reza Abdi
Journal:  Blood       Date:  2010-11-12       Impact factor: 22.113

Review 3.  Bone marrow mesenchymal stem cells: biological properties and their role in hematopoiesis and hematopoietic stem cell transplantation.

Authors:  Charalampos Pontikoglou; Frédéric Deschaseaux; Luc Sensebé; Helen A Papadaki
Journal:  Stem Cell Rev Rep       Date:  2011-09       Impact factor: 5.739

Review 4.  Bone marrow stem cell mobilization in stroke: a 'bonehead' may be good after all!

Authors:  C V Borlongan
Journal:  Leukemia       Date:  2011-07-05       Impact factor: 11.528

Review 5.  Mesenchymal stem cell transplantation in multiple sclerosis.

Authors:  Jeffrey A Cohen
Journal:  J Neurol Sci       Date:  2013-01-04       Impact factor: 3.181

6.  Exploring the enkephalinergic differentiation potential in adult stem cells for cell therapy and drug screening implications.

Authors:  Maryam Hafizi; Behnaz Bakhshandeh; Masoud Soleimani; Amir Atashi
Journal:  In Vitro Cell Dev Biol Anim       Date:  2012-10-06       Impact factor: 2.416

Review 7.  Stem cell therapies in age-related neurodegenerative diseases and stroke.

Authors:  Yuan Wang; Xunming Ji; Rehana K Leak; Fenghua Chen; Guodong Cao
Journal:  Ageing Res Rev       Date:  2016-11-19       Impact factor: 10.895

8.  TNF-α respecifies human mesenchymal stem cells to a neural fate and promotes migration toward experimental glioma.

Authors:  V Egea; L von Baumgarten; C Schichor; B Berninger; T Popp; P Neth; R Goldbrunner; Y Kienast; F Winkler; M Jochum; C Ries
Journal:  Cell Death Differ       Date:  2010-12-03       Impact factor: 15.828

9.  Painting factor H onto mesenchymal stem cells protects the cells from complement- and neutrophil-mediated damage.

Authors:  Yan Li; Wen Qiu; Lingjun Zhang; John Fung; Feng Lin
Journal:  Biomaterials       Date:  2016-06-08       Impact factor: 12.479

10.  Early Immunomodulation by Intravenously Transplanted Mesenchymal Stem Cells Promotes Functional Recovery in Spinal Cord Injured Rats.

Authors:  Jung Hwa Seo; In Keun Jang; Hyongbum Kim; Mal Sook Yang; Jong Eun Lee; Hyo Eun Kim; Yong-Woo Eom; Doo-Hoon Lee; Ji Hea Yu; Ji Yeon Kim; Hyun Ok Kim; Sung-Rae Cho
Journal:  Cell Med       Date:  2011-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.